Faron Pharmaceuticals Oy (FARN) — Working Capital to Net Assets Ratio
Faron Pharmaceuticals Oy (FARN) has a Working Capital to Net Assets ratio of -43.0% as of June 2025. Working capital of GBX6.98 Million (current assets of GBX14.80 Million minus current liabilities of GBX7.83 Million) is measured against net assets of GBX-16.25 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Faron Pharmaceuticals Oy to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Faron Pharmaceuticals Oy Working Capital to Net Assets (2012–2024)
This chart shows how Faron Pharmaceuticals Oy's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of June 2025, the ratio stands at -43.0%, reflecting working capital of GBX6.98 Million against net assets of GBX-16.25 Million GBX. For the complete balance sheet picture, see how large is Faron Pharmaceuticals Oy's balance sheet.
Annual Working Capital to Net Assets for Faron Pharmaceuticals Oy (2012–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Faron Pharmaceuticals Oy from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Faron Pharmaceuticals Oy (FARN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -9.2% | GBX894.00K | GBX-9.76 Million | GBX11.06 Million | GBX10.17 Million | ▼ -49.7 pp |
| 2023 | 40.5% | GBX-6.14 Million | GBX-15.16 Million | GBX8.87 Million | GBX15.01 Million | ▲ +34.1 pp |
| 2022 | 6.5% | GBX-741.00K | GBX-11.48 Million | GBX9.73 Million | GBX10.47 Million | ▼ -159.6 pp |
| 2021 | 166.0% | GBX4.84 Million | GBX2.92 Million | GBX12.02 Million | GBX7.18 Million | ▲ +213.0 pp |
| 2020 | -46.9% | GBX868.00K | GBX-1.85 Million | GBX7.37 Million | GBX6.50 Million | ▼ -241.3 pp |
| 2019 | 194.3% | GBX3.13 Million | GBX1.61 Million | GBX9.20 Million | GBX6.08 Million | ▼ -98.3 pp |
| 2018 | 292.7% | GBX1.08 Million | GBX369.00K | GBX6.83 Million | GBX5.75 Million | ▲ +183.6 pp |
| 2017 | 109.1% | GBX5.17 Million | GBX4.74 Million | GBX13.23 Million | GBX8.06 Million | ▼ -0.8 pp |
| 2016 | 109.9% | GBX11.96 Million | GBX10.88 Million | GBX16.33 Million | GBX4.37 Million | ▲ +6.2 pp |
| 2015 | 103.7% | GBX11.59 Million | GBX11.18 Million | GBX13.79 Million | GBX2.20 Million | ▲ +46.4 pp |
| 2014 | 57.3% | GBX-681.00K | GBX-1.19 Million | GBX981.00K | GBX1.66 Million | ▼ -5.6 pp |
| 2013 | 62.9% | GBX-597.00K | GBX-949.00K | GBX1.14 Million | GBX1.74 Million | ▲ +51.9 pp |
| 2012 | 11.0% | GBX-92.00K | GBX-837.00K | GBX860.00K | GBX952.00K | — |